In summary, in addition to the genetic variations in SPTLC1, the availability of L-serine and L-alanine in patients affects the clinical phenotype and can shift the lipid signature between HSAN1 and ALS. The gene discussed is SPTLC1; the disease is amyotrophic lateral sclerosis.